Triflusal Triflusal Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981. Currently, it is available in 25 countries in Europe, Asia, Africa and America. It is a drug of the salicylate family but it is not a derivative of acetylsalicylic acid (ASA). Trade names include Disgren, Grendis, Aflen and Triflux. Triflusal is a selective platelet antiaggregant through; Triflusal is indicated for; In the 2008 guidelines for stroke management from the European Stroke Organization, triflusal was for the first time recommended as lone therapy, as an alternative to acetylsalicylic acid
Asa language people once spoke Asa, but shifted to Nandi (as opposed to Maasai). Asa language The Asa (Aasá) language, commonly rendered Aasax, was spoken by the Asa people of Tanzania. The language is extinct; ethnic Assa in northern Tanzania remember only a few words they overheard their elders use, and none ever used it themselves. Little is known of the language; what is recorded was probably Aasa lexical words used in a register of Maasai like the mixed language Mbugu. Asa is usually classified as Cushitic, most closely related to Kw'adza. However, it might have retained a non-Cushitic layer from an